Axogen Acquires BioCircuit for $200M to Expand Nerve Repair Portfolio
Florida-based medical technology company Axogen has agreed to acquire BioCircuit Technologies in a $200 million all-cash deal, expected to close by the end of Q4 2026. The acquisition brings on board NerveTape, an FDA-approved sutureless nerve repair device that uses miniature hooks to align and hold severed nerves together for healing. Axogen aims to leverage its sales force and surgeon relationships to accelerate market adoption of NerveTape. Axogen's CEO Michael Dale highlighted the potential of NerveTape to simplify complex nerve surgeries, while CFO Lindsey Hartley described it as an 'attractive growth asset.' The deal also grants access to BioCircuit’s technology platform for future product development and expansion into new indications. However, Axogen faces competition in this space from Tissium's Coaptium Connect device, which uses a light-activated gel within a 3D-printed chamber.
Tickers: $AXGN